B-lymphocyte depletion for the treatment of multiple sclerosis: Now things really get interesting

Expert Review of Neurotherapeutics

Volumn 9, Issue 3, 2009, Pages 309-312

  Matsushita, Takashi ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; RITUXIMAB;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; B LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; EDITORIAL; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INCIDENCE; LYMPHOCYTE DEPLETION; MULTIPLE SCLEROSIS; NONHUMAN; PSORIASIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS; METABOLISM;

B-LYMPHOCYTES; HUMANS; MULTIPLE SCLEROSIS;

EID: 66449084141     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.9.3.309     Document Type: Editorial

References (35)

1. LeBien TW, Tedder TF. B-lymphocytes: how they develop and function. Blood 112, 1570-1579 (2008).
2. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223, 284-299 (2008).
3. + T cell activation in mice. Proc. Natl. Acad. Sci. USA 104, 20882-20887 (2007).
4. Lund FE. Cytokine-producing B lymphocytes - key regulators of immunity. Curr. Opin. Immunol. 20, 1-7 (2008).
5. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008).
6. Bar-Or A, Calabresi PA, Arnold D et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, Phase I trial. Ann. Neurol. 63, 395-400 (2008).
7. McFarland HF. The B cell - old player, new position on the team. N. Engl. J. Med. 358, 664-665 (2008).
8. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol. 4, 557-567 (2008).
9. Uchida J, Lee Y, Hasegawa M et al. Mouse CD20 expression and function. Int. Immunol. 16, 119-129 (2004).
10. Uchida J, Hamaguchi Y, Oliver JA et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659-1669 (2004).
11. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcy receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203, 743-753 (2006).
12. Minard-Colin V, Xiu Y, Poe JC et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcyRIV. Blood 112, 1205-1213 (2008).
13. Hasegawa M, Hamaguchi Y, Yanaba K et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am. J. Pathol. 169, 954-966 (2006).
14. Yanaba K, Hamaguchi Y, Venturi GM, Steeber DA, St. Clair EW, Tedder TF. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J. Immunol. 179, 1369-1380 (2007).
15. Xiu Y, Wong CP, Hamaguchi Y et al. B lymphocytes depletion by CD20 monoclonal antibody prevents diabetes in NOD mice despite isotype-specific differences in FcγR effector functions. J. Immunol. 180, 2863-2875 (2008).
16. DiLillo DJ, Hamaguchi Y, Ueda Y et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol. 180, 361-371 (2008).
17. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Herd M. Rituximab exerts a dual effect in pemphigus vulgaris. J. Invest. Dermatol. 128, 2850-2858 (2008).
18. Stasi R, Del Poeta G, Stipa E et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110, 2924-2930 (2007).
19. Mizoguchi A, Bhan AK. A case for regulatory B cells. J. Immunol. 176, 705-710 (2006).
20. Serra P, Santamaria P. To 'B' regulated: B cells as members of the regulatory workforce. Trends Immunol. 27, 7-10 (2006).
21. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat. Rev. Immunol. 8, 391-397 (2008).
22. Bouaziz J-D, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224, 201-214 (2008).
23. + phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639-650 (2008).
24. Matsushita T, Yanaba K, Bouaziz J-D, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420-3430 (2008).
25. Bettelli E, Baeten D, Jager A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest. 116, 2393-2402 (2006).
26. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest. 116, 2385-2392 (2006).
27. Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184, 2271-2278 (1996).
28. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3, 944-950 (2002).
29. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 56, 2715-2718 (2007).
30. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm. Bowel Dis. 13, 1365-1368 (2007).
31. Benedetti L, Franciotta D, Vigo T et al. Relapses after treatment with rituximab in a patient with multiple sclerosis and anti-myelin-associated glycoprotein polyneuropathy. Arch. Neurol. 64(10), 1531-1533 (2007).
32. Duddy M, Niino M, Adatia F et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178, 6092-6099 (2007).
33. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann. Neurol. 64, 187-199 (2008).
34. Kurosaki T. Paradox of B cell-targeted therapies. J. Clin. Invest. 118, 3260-3263 (2008).
35. StClair WE, Tedder TF. New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum. 54, 1-9 (2006).